Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Australian Nanotechnology Companies Set to Revoltionize Drug Delivery

Abstract:
Interstitial NanoSystems and Quintain NanoSystems Spin Off From NanoVic

Australian Nanotechnology Companies Set to Revoltionize Drug Delivery

MELBOURNE, AUSTRALIA and BOSTON, MA | Posted on May 7th, 2007

Two Australian bio-nanotech companies are set to revolutionize the way that medicine is delivered. Victorian Premier Steve Bracks announced today at BIO 2007 in Boston that Nanotechnology Victoria Ltd (NanoVic) is launching Interstitial NanoSystems (Interstitial NS) and Quintain NanoSystems (Quintain NS) as independent companies. The NanoVic spin-offs are the result of a portfolio of projects and developments built around strategic investment of nearly A$14 million with over a dozen partners since 2004.

Interstitial NanoSystems

Interstitial NS is initially focusing on its pain-free insulin delivery patch for diabetes, while the first product for Quintain NS is a rapid clinical test for the detection of meningitis. "Both diseases have devastating effects on people around the world," said Mr. Bracks. "Any new product that makes it easier to test for a disease or to take a life-saving drug is welcomed." NanoVic is attending BIO 2007 and will have prototypes of a selection of these products on display.

Dr. Bob Irving, Director of Interstitial NS and Quintain NS said, "We are excited at the prospects of the two new companies, Interstitial NS and Quintain NS, commercializing the nanotechnology innovations in delivery and diagnostics, to provide better health outcomes with reduced costs to the community. These companies will help to consolidate the key skills, technologies and manufacturing abilities in areas of nanomedicine, where Australia and Victoria have strength."

The Interstitial NS transdermal delivery patch for insulin has already been tested on animals by the Victorian College of Pharmacy and is expected to begin pre-clinical trials in September. Interstitial NS is working with Melbourne-based company Catapult to produce a portable prototype device to enable self administration. The patches are manufactured by the Victorian company MiniFAB, while the nanostructured drugs are formulated by Eiffel Technology.

Interstitial NS will also commercialize a device for pulmonary delivery of nanoparticulate drugs. The portable personal inhaler uses Surface Acoustic Wave (SAW) technology, with Melbourne-based Charlwood Design designing the prototype pump. Pre-clinical trials are anticipated to start in January 2008. The transdermal delivery technology used by Interstitial NS has already been recognized as "prime technological innovation" by analysts Frost & Sullivan.

Quintain NanoSystems

Quintain NS has a number of products in the pipeline, initially focusing on a diagnostic test for the detection of meningitis. The test uses nanoparticle technology to provide a rapid color-based readout, avoiding lengthy bacterial culturing for identifying the bacteria. Also in development are a number of other diagnostic tools. Nanoparticle-based imaging reagents will enable early detection of disease states in humans. Nanoarray biochips will offer a cost effective method of detection for both salmonella and bovine mastitis, and enzyme biosensor probes are under development for the measurement of sulfite in food and beverages.

####

About NanoVic
Nanotechnology Victoria Ltd is the key organization for delivering nanotechnology research outcomes to Victorian industry. NanoVic has a membership of three universities; Monash, RMIT and Swinburne as research and technology providers, with financial backing from the State Government of Victoria.

For more information, please click here

Contacts:
Media Contact:
Michelle Linn
Linnden Communications
Office: 508-419-1555
Mobile: 774-696-3803

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanomedicine

Return on investment for kit and promotion materials April 24th, 2014

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Announcements

Making graphene work for real-world devices: Fundamental research in phonon scattering helps researchers design graphene materials for applications April 24th, 2014

Return on investment for kit and promotion materials April 24th, 2014

Protecting olive oil from counterfeiters April 24th, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE